Related Experiment Video

Updated: Sep 17, 2026

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Do OKT 3 monoclonal antibodies inhibit T-cell proliferation by blocking the receptor for TCGF?

T Lea

    Immunology Letters
    |January 1, 1982
    PubMed

    Insights

    OKT 3 monoclonal antibodies significantly inhibit T-lymphoblast proliferation by blocking T-cell growth factor (TCGF) binding. This immune response targets the TCGF receptor on activated T-lymphocytes.

    Area of Science:

    • Immunology
    • Cell Biology

    Background:

    • T-lymphoblasts are crucial for immune responses.
    • T-cell growth factor (TCGF) supports T-lymphoblast proliferation.
    • Understanding T-lymphoblast regulation is key to immune modulation.

    Purpose of the Study:

    • To investigate the inhibitory effects of OKT 3 monoclonal antibodies on T-lymphoblast proliferation.
    • To determine the mechanism by which OKT 3 antibodies affect T-lymphoblast growth.

    Main Methods:

    • Utilized OKT 3 monoclonal antibodies in varying concentrations.
    • Assessed T-lymphoblast proliferation rates.
    • Employed purified radiolabeled TCGF to study growth factor binding.

    Main Results:

    • OKT 3 antibodies demonstrated strong, dose-dependent inhibition of T-lymphoblast proliferation.
    • Inhibition reached nearly 70% at 10 micrograms/ml concentration.
    • Inhibition occurred at the level of growth factor binding to the T-cell receptor.

    Conclusions:

    • OKT 3 monoclonal antibodies effectively inhibit T-lymphoblast proliferation.
    • The mechanism involves interference with T-cell growth factor binding.
    • These antibodies likely interact with the TCGF receptor on activated T-lymphocytes.

    More Related Videos

    Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

    Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

    Published on: January 22, 2019

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

    Published on: May 16, 2020

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    TGF - β Signaling Pathway01:16

    TGF - β Signaling Pathway

    The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
    T Cell Activation and Clonal Selection01:22

    T Cell Activation and Clonal Selection

    T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
    Naive T cells that have not yet encountered an antigen express two primary CD...
    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.